Photo from Reuben Ben-David/X
May 13, 2024, 09:47
Reuben Ben-David: Gem/Doce is gaining grounds in the treatment of NMIBC
Reuben Ben-David, Society of Urological Oncology (SUO) fellow at the Mount Sinai Hospital NYC, shared on X:
“Excited about our latest publication! Gem/Doce induction plus maintenance is superior to induction only.
The use of 2 grams of gemcitabine improved all grades of recurrence but didn’t decrease high-grade recurrences over 1 gram of gemcitabine.
Gem/Doce is gaining grounds in the treatment of NMIBC.” .
Source: Reuben Ben-David/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54